Deborah H. Telman, an insider at Gilead Sciences Inc (GILD), sold 43,676 shares at $122.30 each on November 11, 2025, totaling $5.34 million. Following this transaction, Telman retains 43,676 shares in the company.
Gilead Sciences, headquartered in Foster City, California, is a biopharmaceutical firm focused on developing medicines for unmet medical needs, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company has a market capitalization of $156.7 billion and a trailing P/E ratio of 19.32. Its upcoming earnings reports are anticipated on April 21, 2026, with an estimated EPS of $2.07 and revenue of $7.2 billion.
Insider transactions are reported to the SEC, providing transparency into executive stock movements. While this sale represents one data point for investors, it is important to consider broader patterns of insider activity rather than isolated transactions. Such decisions reflect various personal or financial factors that may not necessarily indicate a negative outlook for the company.